A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms GALAXI
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Apr 2018 Planned primary completion date changed from 16 Aug 2022 to 3 Jun 2022.
    • 06 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 13 Apr 2018.
    • 30 Mar 2018 Planned primary completion date changed from 3 Jun 2022 to 16 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top